Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.06), $0.76 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $325 million versus the consensus estimate of $174.13 million.

GUIDANCE:

Ionis Pharmaceuticals sees Q1 2024 revenue of $575 million, versus the consensus of $635.3 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.